Minerva Neurosci Stock Price, News & Analysis

Minerva Neurosciences (Nasdaq: NERV) has entered an agreement with Royalty Pharma (Nasdaq: RPRX) to sell its royalty interest in seltorexant for $60 million upfront and up to $95 million in milestone payments. Seltorexant is in Phase 3 development targeting major depressive disorder with insomnia. The funds will support Minerva's lead compound, roluperidone, also in Phase 3 for schizophrenia. Minerva will earn mid-single digit royalties on seltorexant's net sales, enhancing its financial position.

Minerva Neurosciences (NASDAQ: NERV) announced it received meeting minutes from the FDA regarding its investigation of roluperidone for negative symptoms in schizophrenia. The FDA raised concerns about the Phase 2b and Phase 3 studies, indicating that the data may not support an NDA submission due to insufficient evidence of effectiveness and the lack of adequate trials. However, Minerva intends to bridge the data gap with additional studies and is optimistic about addressing FDA concerns, continuing its development efforts.

Minerva Neurosciences (NASDAQ: NERV) announced its participation in the Jefferies Virtual London Healthcare Conference on November 17, 2020, at 12:55 p.m. GMT (7:55 a.m. EST). The presentation will be available as a live webcast and can be accessed through the company’s investor relations website. Minerva focuses on developing innovative therapies for CNS disorders, with key compounds including roluperidone for schizophrenia and MIN-301 for Parkinson’s disease. For further details, visit the company's website.

Minerva Neurosciences (NASDAQ: NERV) reported its Q3 2020 financial results, revealing a net loss of $8.1 million, significantly improved from a loss of $14.0 million in Q3 2019. Collaborative revenue surged to $41.2 million, attributed to the termination of a licensing agreement with Janssen. R&D expenses dropped to $4.6 million, while G&A expenses decreased to $3.5 million. The FDA has granted a Type C meeting for roluperidone on November 10, 2020, to discuss clinical data and potential NDA submission. An update is expected in December 2020.

Minerva Neurosciences (NASDAQ: NERV) will release its third-quarter 2020 financial results on November 2, 2020, at 8:30 a.m. ET. The conference call will provide business updates and insights into their clinical-stage biopharmaceutical developments targeting central nervous system disorders. Key products in their portfolio include roluperidone for schizophrenia and MIN-301 for Parkinson’s disease. Investors can access the call by dialing the provided numbers and a webcast will be available for later viewing.

Minerva Neurosciences, a clinical-stage biopharmaceutical company, will participate in Citi's 15th Annual BioPharma Virtual Conference on September 9, 2020, at 1:30 p.m. ET. The panel discussion focuses on "Emerging Therapies for Psychiatric Disorders." Investors can access the presentation live and on-demand via the company's website. Minerva’s product pipeline includes roluperidone for schizophrenia and seltorexant for insomnia, with additional projects targeting Parkinson’s disease.

Minerva Neurosciences, a clinical-stage biopharmaceutical firm focused on CNS disorders, will present at the JMP Securities CNS Forum on August 19, 2020, at 10:30 a.m. ET. This virtual event will be accessible via a webcast on the company's investor relations website. Minerva's product pipeline includes roluperidone for schizophrenia, seltorexant for insomnia and MDD, and MIN-301 for Parkinson's disease. The stock trades on NASDAQ under the symbol NERV.

Minerva Neurosciences (NASDAQ: NERV) reported Q2 2020 financial results, highlighting a net income of $29.5 million, or $0.75 per share, a turnaround from a loss of $12.5 million in the same period last year. The company recognized $41.2 million in collaborative revenue following its decision to opt out of the seltorexant agreement with Janssen. R&D expenses dropped to $5.8 million from $8.3 million year-over-year. However, the Phase 3 trial for roluperidone did not meet its primary endpoints, though some statistically significant improvements were observed.

Minerva Neurosciences (NASDAQ: NERV) announced a webcast on June 5, 2020, to present additional results from its Phase 3 trial focusing on negative symptoms of schizophrenia. This event replaces a previously scheduled session and will feature key opinion leaders who will discuss the findings. The company continues to develop roluperidone, a candidate for schizophrenia, alongside other compounds for insomnia and Parkinson's disease. Investors can participate via a conference call or listen to the live webcast, with an archived version available for 90 days.